Green LifeScience Co Ltd
Green LifeScience Co Ltd is a South Korean pharmaceutical company that develops and commercializes biopharmaceutical products, primarily in the areas of oncology and autoimmune diseases.
Business. Green LifeScience Co Ltd (114450.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Green LifeScience Co Ltd (114450.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue breakdowns are not available.
Green LifeScience maintains a strong liquidity position, with a current ratio of 3.21 and cash and equivalents of KRW 5.65 billion, which exceeds its short-term obligations. The company's debt-to-equity ratio is 0.14, indicating a conservative capital structure with limited leverage.
Profitability metrics show a return on equity of 2.94% and a return on assets of 2.46%, which are below the industry median for pharmaceutical firms. The company's operating margin is 10.99% (calculated from operating income of KRW 722 million on revenue of KRW 6.54 billion), suggesting room for improvement in cost control or pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in South Korea, where the company is headquartered.
Green LifeScience's revenue growth is expected to remain stable, with no significant changes in the current fiscal year or the next. The company's capital expenditure of KRW 39 million is minimal, indicating a low investment in new capacity or R&D infrastructure.
The company's risk profile is low, with no immediate liquidity or dilution concerns. The absence of dilution sources in the latest filings and the low dilution potential suggest that the company is not planning to raise additional equity in the near term.
Recent filings and transcripts do not indicate any material events or strategic shifts. The company continues to focus on its core therapeutic areas and has not disclosed any major partnerships or product launches in the latest available documents.
- Green LifeScience maintains a conservative capital structure with a low debt-to-equity ratio and strong liquidity.
- The company's profitability metrics are below industry medians, indicating potential inefficiencies or pricing pressures.
- Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The company is not currently planning to raise additional equity, suggesting low dilution risk.
- Minimal capital expenditure indicates a low investment in growth or R&D.
Bull / Bear case
Generated · model-assistedRevenue surged 62.3% year-over-year to 40.3 billion KRW, demonstrating strong top-line growth momentum in the latest fiscal period.
Low dilution, liquidity, and credit risk flags suggest a stable financial foundation with minimal immediate threats to shareholder value.
Cash conversion ratio of -1.04 places the company in the bottom quartile of the pharmaceutical cohort, highlighting weak cash management.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Green LifeScience Co Ltd Market data — financials · 2026-05-26